Tirzepatide and retatrutide in the same week: shared receptors, no trial combining them, two half-lives near 6 days, and the arithmetic of a combined total.
No trial has given tirzepatide and retatrutide to the same person, and the one label that addresses it advises against it: the Zepbound label states that "coadministration with other tirzepatide-containing products or with any GLP-1 receptor agonist is not recommended" (read 2026-11-03), and retatrutide is a GLP-1 receptor agonist. Retatrutide has no label, and its phase 3 trials excluded anyone who had used a weight-loss drug in the 90 days before screening. What can be stated is what each molecule does, how long each stays, and what a combined weekly total does and does not mean. This page sets that out. It reports; it recommends no dose and no ratio.
Moving from one to the other, rather than combining them, is a different question, covered on tirzepatide to retatrutide; the two dose ladders side by side are on retatrutide vs tirzepatide dosage.
Shared receptors
|
Tirzepatide |
Retatrutide |
| GIP receptor |
Yes |
Yes |
|---|
| GLP-1 receptor |
Yes |
Yes |
|---|
| Glucagon receptor |
No |
Yes |
|---|
| Status (2026-11-03) |
FDA-labelled (Zepbound, Mounjaro) |
Investigational; Lilly plans a US application in Q1 2027 |
|---|
| Weekly dose range in the record |
2.5–15 mg (label) |
1–12 mg (phase 2); 4, 9, 12 mg (phase 3) |
|---|
| Half-life |
about 5–6 days (Zepbound label) |
about 6 days (PMID 36354040) |
|---|
Two of retatrutide's three targets are the whole of tirzepatide's mechanism. Using both therefore doubles up on GIP and GLP-1 signalling; the only activity retatrutide adds that tirzepatide lacks is at the glucagon receptor. Eli Lilly's July 2026 release describes retatrutide as "an investigational molecule that cannot be legally sold or marketed for human use".
What the registry and the literature contain
- ClinicalTrials.gov, search "tirzepatide AND retatrutide" on 2026-11-03: 3 records. NCT06662383 (TRIUMPH-5, 800 adults) randomises to one drug or the other and measures percent weight change at week 80. NCT07165028, a liver-disease master protocol (4,500 planned), runs a tirzepatide arm and a retatrutide arm, each against its own placebo. NCT07226947 (100 planned) tests a smartwatch against usual exercise guidance in people on incretin therapy. None gives both drugs together.
- Trial eligibility: TRIUMPH-1 excludes anyone who has "taken weight loss drugs, including over-the-counter medications, within 90 days prior to screening". The same exclusion appears in the other phase 3 retatrutide records read on this site on 2026-09-25.
- PubMed, 2026-11-03: 115 records mention both molecules in the title or abstract; 5 also mention co-administration or combination. Four are reviews and one is a rat study of cagrilintide with retatrutide (PMID 42744908). No human data.
The figures that circulate for "stacking" ratios come from forum posts and short videos, not from any trial, and are not reproduced here.
Two long half-lives in one week
Both molecules are dosed weekly because both clear slowly. Using a simple one-compartment estimate — fraction left after a week = 0.5^(7 ÷ half-life):
|
Half-life used |
Left after 1 week |
After 2 weeks |
After 3 weeks |
Weekly steady-state build-up |
| Tirzepatide |
5 days |
37.9% |
14.4% |
5.4% |
×1.61 |
|---|
| Retatrutide |
6 days |
44.5% |
19.8% |
8.8% |
×1.80 |
|---|
The build-up factor (1 ÷ (1 − fraction left)) is how much higher the level settles than a single dose would give once weekly injections have run for about a month. Anyone who uses one and then adds or switches to the other carries the first drug's tail for three to four weeks; on that point the arithmetic is the same whether the second drug is added or substituted.
The arithmetic of a combined weekly total
A weekly total of "9 mg" made of 5 mg tirzepatide and 4 mg retatrutide is not a 9 mg dose of anything. The two molecules differ in size and potency: in their own trials, 8 mg of retatrutide produced −22.8% at 48 weeks (phase 2, PMID 37366315) and 10 mg of tirzepatide −19.5% at 72 weeks (SURMOUNT-1, PMID 35658024), different trials and populations, so even those figures do not convert one milligram into the other. What a combined total does measure is volume. For a vial, units on a U-100 syringe = milligrams ÷ concentration in mg/mL × 100:
| Amounts drawn (each at 10 mg/mL) |
Tirzepatide |
Retatrutide |
Total volume |
| 2.5 mg + 2 mg |
25 units |
20 units |
45 units (0.45 mL) |
| 5 mg + 4 mg |
50 |
40 |
90 units (0.90 mL) |
| 7.5 mg + 4 mg |
75 |
40 |
115 units (1.15 mL) |
The third row already exceeds a single 1 mL syringe at that concentration. No published study reports whether the two solutions are compatible in one syringe.
Side effects of each, alone
Both drugs' main adverse events are gastrointestinal and dose-related. In TRIUMPH-2, Eli Lilly reported diarrhoea in 27.4%, 33.5% and 33.6% of the 4, 9 and 12 mg retatrutide groups against 13.2% on placebo, and nausea in 13.7%, 20.8% and 28.0% against 8.0% (release of 2026-07-23). The tirzepatide labels escalate in 2.5 mg steps "to reduce the risk of gastrointestinal adverse reactions". Whether these add, overlap or compound when the two are used together has not been measured.
What is not established
Every outcome of the combination: weight effect, gastrointestinal tolerance, heart rate, pancreatic and gallbladder events, and what happens on stopping. The retatrutide stacks on this site cover pairings with different mechanisms. Medibact's tirzepatide guide and retatrutide guide cover each compound. Decisions about any medicine belong with the prescriber.
Sources and dates
Opened 2026-11-03: the openFDA label record for ZEPBOUND (set id 487cd7e7-434c-4925-99fa-aa80b1cc776b, effective 2026-08-28), sections 2 and 12.3; Eli Lilly's TRIUMPH releases of 2026-05-21 and 2026-07-23 (PR Newswire); the ClinicalTrials.gov v2 API search "tirzepatide AND retatrutide" and the records NCT06662383, NCT07165028, NCT07226947 and NCT05929066 (eligibility); NCBI E-utilities searches of PubMed and the abstracts or summaries of PMIDs 36354040, 37366315, 35658024 and 42744908. Half-life and unit arithmetic by this site. Corrections go to the contact page.
